ASP Isotopes (ASPI) Cash & Equivalents (2021 - 2026)

ASP Isotopes' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $207.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 270.49% year-over-year to $207.3 million in Q1 2026; TTM through Mar 2026 was $207.3 million, a 270.49% increase from a year earlier, with the FY2025 full-year figure at $267.4 million, up 332.06% from the prior year.
• Cash & Equivalents slipped to $207.3 million in Q1 2026 per ASPI's latest filing, from $267.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $267.4 million in Q4 2025 and bottomed at $431565.0 in Q3 2022.
• The 5-year median for Cash & Equivalents is $23.9 million (2024), against an average of $53.3 million.
• Across the five-year window, Cash & Equivalents slipped 19.11% in 2022 and soared 2155.18% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $2.4 million in 2022, then soared by 231.0% to $7.9 million in 2023, then soared by 682.63% to $61.9 million in 2024, then soared by 332.06% to $267.4 million in 2025, then decreased by 22.46% to $207.3 million in 2026.
• Per Business Quant, the three latest ASPI Cash & Equivalents figures stand at $207.3 million (Q1 2026), $267.4 million (Q4 2025), and $113.9 million (Q3 2025).